Drugs for Lymphoma

Adcetris (brentuximab vedotin)

Adcetris is a CD30-directed antibody-drug conjugate used for the treatment of patients with several types of classical Hodgkin lymphoma, including untreated stage III or IV disease.

Seagen Secure offers 1 financial assistance program for patients using Adcetris:

SeaGen Secure Patient Assistance Program

Patients who are uninsured and meet certain financial criteria will be eligible to receive Adcetris at no cost. With this program, assistance begins with a temporary 3-month period.

Keytruda (pembrolizumab)

Keytruda is a PD-1 inhibitor used for the treatment of adults with relapsed or refractory classical Hodgkin lymphoma. Keytruda is also used for the treatment of pediatric patients with refractory classical Hodgkin lymphoma, or classical Hodgkin lymphoma that has relapsed after 2 or more lines of therapy.

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda for free. Eligible patients must have a household income of $64,400 or less for individuals, $87,100 or less for couples, or $132,500 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for medicines, may request that an exception be made, provided their household income is not above a set limit.

Opdivo (nivolumab)

Opdivo is a PD-1 inhibitor used for the treatment of adults with classical Hodgkin lymphoma that has relapsed or progressed after autologous stem-cell transplant and Bendeka, or after 3 or more lines of systemic therapy that included autologous transplant.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductibles, copay, or co-insurance costs for eligible, privately insured patients who have been prescribed Opdivo. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually per medication.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Opdivo may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.

Adcetris (brentuximab vedotin)

Adcetris is a CD30-directed antibody-drug conjugate used for the treatment of patients with several types of systemic anaplastic large-cell lymphoma, a form of non-Hodgkin lymphoma (NHL). Adcetris is also used for patients with other types of CD30-expressing untreated peripheral T-cell lymphomas (PTCL), alone or in combination with cyclophosphamide, doxorubicin, and prednisone; and for patients with primary cutaneous anaplastic large-cell lymphoma, or CD30-expressing mycosis fungoides, after systemic therapy.

Seagen Secure offers 1 financial assistance program for patients who have been prescribed Adcetris:

Seagen Secure Patient Assistance Program

Patients who are uninsured and meet certain financial criteria will be eligible to receive Adcetris at no cost. With this program, assistance begins with a temporary 3-month period.

Beleodaq (belinostat) for Injection

Beleodaq is a histone deacetylase (HDAC) inhibitor used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, a type of NHL.

Acrotech Biopharma, through its Specialty Therapy Access Resources (STAR) program, offers 2 financial assistance programs for patients who are prescribed Beleodaq:

Bendeka (bendamustine HCl) Injection

Bendeka is an alkylating drug used for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or after 6 months of Rituxan therapy.

Teva offers 1 financial assistance program for patients using Bendeka:

Teva Cares Foundation Patient Assistance Program

Patients without prescription drug coverage who meet specific financial criteria may receive Bendeka for free. The financial criteria specify that the patient’s annual income must not exceed $60,700 for 1 person, $82,300 for 2 people, $103,900 for 3 people, $125,000 for 4 people, or $147,100 for 5 people.

Brukinsa (zanubrutinib)

Brukinsa is a Bruton kinase inhibitor used for the treatment of adults with Waldenström’s macroglobulinemia, a rare type of NHL.

BeiGene offers 3 financial assistance programs for patients who are prescribed Brukinsa:

BeiGene Free Product Assistance

This program provides Brukinsa for free for patients who have no insurance or insufficient insurance. This program has certain financial and eligibility requirements.

Folotyn (pralatrexate)

Folotyn is a folate analog metabolic inhibitor used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, a type of NHL.

Acrotech Biopharma, through its Specialty Therapy Access Resources (STAR) program, offers 2 financial assistance programs for patients who are prescribed Folotyn:

Imbruvica (ibrutinib) Capsules/Tablets

Imbruvica is a Bruton tyrosine kinase inhibitor used for the treatment of patients with Waldenström’s macroglobulinemia, a type of NHL.

Pharmacyclics’ You&i Support Program offers 2 financial assistance programs for patients using Imbruvica:

You&i Instant Savings Program

Patients with private insurance will pay no more than $10 monthly for Imbruvica. Eligible patients may qualify for instant savings on their commercial insurance copay, deductible, and co-insurance medication costs for Imbruvica.

Johnson & Johnson Patient Assistance Foundation

This program provides Imbruvica free of charge to patients who meet certain financial limits and are uninsured, underinsured, or enrolled in Medicare Part D.

Mozobil (plerixafor)

Mozobil is a hematopoietic stem-cell mobilizer used, in combination with granulocyte colony-stimulating factor, for the treatment of patients with non-Hodgkin lymphoma (NHL).

Sanofi Aventis, through Sano Cares North America, offers 1 financial assistance program to patients using Mozobil:

Sanofi Patient Assistance Connection

This program provides Mozobil at no cost to patients who have no insurance coverage or their insurance does not cover the cost of Mozobil, and they meet program eligibility requirements and have an annual household income of 400% or less of the current federal poverty level. Patients with Medicaid must provide documentation of Medicaid denial before being assessed for patient assistance eligibility. Patients enrolled in Medicare Part D must meet certain financial criteria.

Poteligeo (mogamulizumab-kpkc)

Poteligeo is a CCR4-directed monoclonal antibody used for the treatment of adults who have relapsed or refractory mycosis fungoides, a type of non-Hodgkin lymphoma (NHL), and for patients with Sézary syndrome (cutaneous T-cell lymphoma), a rare type of NHL, after at least 1 systemic therapy.

Kyowa Kirin Cares offers 2 financial assistance programs for patients who have been prescribed Poteligeo:

Kyowa Kirin Cares Co-Pay Assistance Program

Patients with private insurance may be eligible to receive copay assistance for their Poteligeo prescription.

Kyowa Kirin Cares Patient Assistance Program

Uninsured patients whose annual gross income is less than or equal to 400% of the federal poverty level may be eligible to receive financial assistance for Poteligeo.

Rituxan (rituximab)

Rituxan is a CD20-directed cytolytic antibody used for the treatment of relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin lymphoma (NHL) as a single agent; first-line treatment of follicular, CD20-positive, B-cell NHL, in combination with first-line chemotherapy, and, in patients achieving a complete or partial response to a rituximab drug, in combination with chemotherapy, as single-agent maintenance therapy. Rituxan is also used for the treatment of non-progressing, low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line chemotherapy, and for first-line treatment of diffuse large B-cell, CD20-positive NHL, in combination with anthracycline-based chemotherapy regimens.

Genentech Oncology offers 2 financial assistance programs for patients using Rituxan:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Rituxan, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Rituxan free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Rituxan is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.

Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn) Injection

Rylaze is an asparagine-specific enzyme used as part of a multi-drug chemotherapy regimen for the treatment of acute lymphoblastic lymphoma, a type of NHL, in patients aged 1 month or older who have hypersensitivity to E. coli-derived asparaginase.

JazzCares offers 2 financial assistance programs for patients using Rylaze:

Truxima (rituximab-abbs)

Truxima, a biosimilar to Rituxan, is a CD20-directed cytolytic antibody used for the treatment of patients with relapsed or refractory low-grade or follicular CD20-positive B-cell non-Hodgkin lymphoma (NHL) as a single agent, or for patients with untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a response to Rituxan plus chemotherapy, as a single-agent maintenance therapy. Truxima is also used, alone, for patients with non-progressing (or stable), low-grade, CD20-positive, B-cell NHL, after cyclophosphamide, vincristine, and prednisone chemotherapy.

Teva offers 2 financial assistance programs for patients who have been prescribed Truxima:

Truxima Patient Savings Program

Eligible patients with private insurance may pay as little as $0 for Truxima, with a maximum annual limit of $25,000. The program may cover eligible out-of-pocket costs incurred by the patient for Truxima within 90 days before program enrollment.

Teva Cares Foundation Patient Assistance Program

This program provides Truxima at no cost to patients who do not have insurance or whose insurance does not cover Truxima. Patients with health insurance must try other types of assistance before they can be approved for this program. Uninsured patients must meet certain financial requirements.

Valchlor (mechlorethamine)

Valchlor is an alkylating drug used for the topical treatment of stage IA or stage IB mycosis fungoides-type cutaneous T-cell lymphoma (a type of NHL), in patients who have received skin-directed therapy.

Helsinn offers 1 financial assistance program for patients who have been prescribed Valchlor:

Valchlor Co-pay Program

Eligible patients who have commercial health insurance whose copay or co-insurance is more than $10 per prescription of Valchlor will pay no more than $10 per prescription in out-of-pocket copay costs for Valchlor.

Xalkori (crizotinib) Capsules

Xalkori is a kinase inhibitor used for the treatment of young patients aged 1 to 21 years with relapsed or refractory systemic anaplastic large-cell lymphoma (a rare type of NHL) and ALK mutation.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Xalkori:

Pfizer Oncology Together Co-Pay Savings Program

This program assists eligible patients who have commercial or private insurance so that their copay for Xalkori is $0 monthly, with a maximum savings of $25,000 annually.

Pfizer Patient Assistance Program

This program serves patients who are uninsured and patients with government insurance. Uninsured patients may qualify to receive Xalkori for free, or at a savings. Eligible patients with government insurance who cannot find independent charitable foundation support may receive Xalkori for free.

Yescarta (axicabtagene ciloleucel)

Yescarta is a CD19-directed genetically modified CAR T-cell immunotherapy used, after 2 or more lines of systemic therapies, for the treatment of adults with relapsed or refractory large B-cell lymphoma (a type of NHL), including primary mediastinal large B-cell lymphoma or high-grade B-cell lymphoma.

Kite Pharma offers 1 patient assistance program for patients who have been prescribed Yescarta:

Kite Konnect

This program helps patients and healthcare teams throughout treatment with Yescarta. (For more information, call 844-454-5483.)

Zolinza (vorinostat) Capsules

Zolinza is a histone deacetylase inhibitor used for the treatment of patients with cutaneous T-cell lymphoma (a type of NHL), that is progressive, persistent, or recurrent with or after 2 systemic therapies.

Merck offers 1 financial assistance program for patients who have been prescribed Zolinza:

Merck Patient Assistance Program

Uninsured patients who cannot afford to pay for Zolinza and have a household income of $51,520 or less for individuals, $69,680 or less for couples, or $106,000 or less for a family of 4, may qualify to receive their medication for free.

Breyanzi (lisocabtagene maraleucel)

Breyanzi is a CD19-directed, genetically modified CAR T-cell immunotherapy, used for the treatment of adults with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified and DLBCL arising from indolent lymphoma; high-grade B-cell lymphoma; and primary mediastinal large B-cell lymphoma, in patients who have received 2 or more lines of systemic therapy.

Juno Therapeutics, through Cell Therapy 360, offers 2 financial assistance programs to patients using Breyanzi:

Cell Therapy 360 Copay Program

Eligible patients who have commercial or private insurance may receive benefits of up to $10,000 in out-of-pocket costs for Breyanzi through this program.

Cell Therapy 360 Patient Assistance Program

Eligible patients who are uninsured or underinsured and who have a household income of no more than 600% of the federal poverty level may receive Breyanzi through this program.

Keytruda (pembrolizumab)

Keytruda is a PD-1 inhibitor used for the treatment of pediatric and adult patients with refractory primary mediastinal large B-cell lymphoma, or patients whose disease relapsed (returned) after 2 or more therapies.

Merck offers 2 financial assistance programs for patients who are prescribed Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $64,400 or less for individuals, $87,100 or less for couples, or $132,500 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines, may request that an exception be made, provided their household income is not above a set limit.

Kymriah (tisagenlecleucel)

Kymriah is a CD19-directed genetically modified CAR T-cell immunotherapy used for the treatment of adults with relapsed or refractory large B-cell lymphoma (a type of NHL) after 2 or more systemic therapies, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified; high-grade B-cell lymphoma; and DLBCL arising from follicular lymphoma.

Novartis’ Patient Assistance NOW Oncology offers 1 financial assistance program for patients who have been prescribed Kymriah:

Kymriah Cares

This program offers financial assistance to eligible patients to help them access Kymriah. Patients must meet program eligibility criteria to qualify for support. Patients should work with their treatment center to submit a Service Request Form for Patient Support to Kymriah Cares.

Monjuvi (tafasitamab-cxix)

Monjuvi is a CD19-directed cytolytic antibody used, in combination with Revlimid, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, in patients who are not eligible for autologous stem-cell transplant.

MorphoSys’s My Mission Support offers 2 financial assistance programs for patients who have been prescribed Monjuvi:

My Mission Support Copay Assistance Program

Through this program, eligible patients who have commercial or private insurance may be able to pay as little as $0 for Monjuvi, with a maximum annual benefit limit of $25,000.

MorphoSys Foundation Patient Assistance Program

Eligible patients who do not have insurance, or whose copay responsibility through their insurer presents a financial hardship, may be able to receive Monjuvi at no cost. The patient’s income must be less than $82,000 for an individual, or $170,000 for a family of 4.

Polivy (polatuzumab vedotin-piiq) for Injection

Polivy is a CD79b-directed antibody-drug conjugate used, in combination with Bendeka and Rituxan, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, after at least 2 previous therapies.

Genentech Oncology offers 2 financial assistance programs for patients who have been prescribed Polivy:

Genentech Oncology Co-pay Assistance Program

Patients with private insurance will pay just a $5 copay per prescription or infusion of Polivy, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Polivy free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Polivy is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.

Rituxan Hycela (rituximab/hyaluronidase human) Injection

Rituxan Hycela is a combination of rituximab, a CD20- directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, used for the treatment of patients with untreated diffuse large B-cell lymphoma (DLCBL), in combination with chemotherapy with anthracycline-based chemotherapy regimens.

Genentech Oncology offers 2 financial assistance programs for patients using Rituxan Hycela:

Genentech Oncology Co-pay Assistance Program

Patients with private insurance will pay just a $5 copay per prescription or infusion of Rituxan Hycela, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Rituxan Hycela free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Rituxan Hycela is also provided free for patients who are unable to afford their outof- pocket costs and cannot find other financial assistance.

Yescarta (axicabtagene ciloleucel)

Yescarta is a CD19-directed genetically modified CAR T-cell immunotherapy used, after 2 or more lines of systemic therapies, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, or DLBCL arising from follicular lymphoma.

Kite Pharma offers 1 patient assistance program for patients using Yescarta:

Kite Konnect

This program helps patients and healthcare teams throughout treatment with Yescarta. (For more information call 844-454-5483.)

Zynlonta (loncastuximab tesirine-lpyl) Injection

Zynlonta is a CD19-directed antibody and an alkylating drug conjugate for the treatment of adults with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified; DLBCL arising from low-grade lymphoma; and high-grade B-cell lymphoma, in patients who have received 2 or more lines of systemic therapy.

ADC Therapeutics, through ADVANCING Patient Support, offers 2 financial assistance programs for patients using Zynlonta:

Aliqopa (copanlisib) for Injection

Aliqopa is a kinase inhibitor used for the treatment of adult patients with relapsed follicular lymphoma who have received at least 2 systemic therapies.

Aliqopa Resource Connections offers 2 financial assistance programs for patients using Aliqopa:

Aliqopa $0 Co-Pay Program

This program allows patients with private insurance to pay $0 copay for Aliqopa, with a yearly savings of up to $25,000.

Bayer US Patient Assistance Foundation

This foundation provides Aliqopa free for patients who are uninsured or underinsured and meet certain eligibility criteria.

Breyanzi (lisocabtagene maraleucel)

Breyanzi is a CD19-directed, genetically modified CAR T-cell immunotherapy, used for the treatment of adults with relapsed or refractory large B-cell lymphoma, including follicular lymphoma grade 3B, in patients who have received 2 or more lines of systemic therapy.

Juno Therapeutics, through Cell Therapy 360, offers 2 financial assistance programs to patients using Breyanzi:

Cell Therapy 360 Copay Program

Eligible patients who have commercial or private insurance may receive benefits of up to $10,000 in out-of-pocket costs for Breyanzi through this program.

Cell Therapy 360 Patient Assistance Program

Eligible patients who are uninsured or underinsured and who have a household income of no more than 600% of the federal poverty level may receive Breyanzi through this program.

Copiktra (duvelisib)

Copiktra is a dual PI3 kinase inhibitor used for the treatment of adults with relapsed or refractory follicular lymphoma, after at least 2 other therapies.

Secura Bio, through Secura Care, offers 3 financial assistance programs for patients using Copiktra:

Secura Bio Quickstart Program

Through this program, patients who have a delay of 5 days or more in obtaining prior authorization can receive the first cycle of Copiktra at no cost.

Gazyva (obinutuzumab)

Gazyva is a CD20-directed cytolytic antibody used, in combination with bendamustine followed by Gazyva alone, for the treatment of patients with follicular lymphoma whose disease relapsed after, or is refractory to, a rituximab-containing regimen; and in combination with chemotherapy followed by Gazyva alone in patients achieving a partial remission, for adults with previously untreated advanced (stage II bulky, III, or IV) follicular lymphoma.

Genentech Oncology offers 2 financial assistance programs for patients using Gazyva:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Gazyva, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Gazyva free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Gazyva is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.

Revlimid (lenalidomide) Capsules

Revlimid is a thalidomide analog used for the treatment of patients with previously treated follicular lymphoma, in combination with Rituxan or a biosimilar to Rituxan.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Revlimid:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductible, copay, or co-insurance costs for eligible patients with private insurance who have been prescribed Revlimid. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including the BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Revlimid, may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual, or $52,260 for a family of 2.

Rituxan Hycela (rituximab/hyaluronidase human) Injection

Rituxan Hycela is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, used for the treatment of patients with relapsed or refractory follicular lymphoma as a single agent; for patients with untreated follicular lymphoma, in combination with first-line chemotherapy; and for patients achieving a complete or partial response to rituximab and chemotherapy, as a single-drug maintenance therapy. Rituxan Hycela is also used, as a single medication, for the treatment of patients with non-progressing or stable follicular lymphoma after first-line chemotherapy with cyclophosphamide, vincristine, and prednisone.

Genentech Oncology offers 2 financial assistance programs for patients using Rituxan Hycela:

Genentech Oncology Co-pay Assistance Program

Patients with private insurance will pay just a $5 copay per prescription or infusion of Rituxan Hycela, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription fill occurred within 180 days prior to enrollment in this program.

Genentech Patient Foundation

This foundation provides Rituxan Hycela free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Rituxan Hycela is also provided free for patients who are unable to afford their outof- pocket costs and cannot find other financial assistance.

Tazverik (tazemetostat) Tablets

Tazverik is a methyltransferase inhibitor used for the treatment of adults with relapsed or refractory follicular lymphoma and EZH2 mutation, as detected by an FDA approved test, after at least 2 previous systemic therapies. Tazverik is also used for adults with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.

Epizyme offers 4 financial assistance programs for patients who are prescribed Tazverik:

Ukoniq (umbralisib) Tablets

Ukoniq is a kinase inhibitor and PI3K-delta and CK1-epsilon, used for the treatment of adults with relapsed or refractory follicular lymphoma who have received 3 or more previous lines of systemic therapy.

TG Therapeutics offers 4 financial assistance programs for patients using Ukoniq:

Yescarta (axicabtagene ciloleucel)

Yescarta is a CD19-directed genetically modified autologous T-cell immunotherapy used for the treatment of adults with relapsed or refractory follicular lymphoma who have received 2 or more lines of systemic therapy.

Kite Pharma offers 1 patient support program for patients who have been prescribed Yescarta:

Kite Konnect

This program helps patients and healthcare teams throughout treatment with Yescarta. (For more information call 844-454-5483.)

Zevalin (ibritumomab tiuxetan)

Zevalin is a CD20-directed radiotherapeutic antibody used for the treatment of patients with relapsed or refractory, lowgrade or follicular B-cell non-Hodgkin lymphoma, or patients with untreated follicular lymphoma who achieve a partial or complete response to first-line chemotherapy.

Acrotech Biopharma, through its Specialty Therapy Access Resources (STAR) program, offers 2 financial assistance programs for patients receiving Zevalin:

Zydelig (idelalisib) Tablets

Zydelig is a kinase inhibitor used for the treatment of patients with follicular B-cell non-Hodgkin lymphoma.

Zydelig AccessConnect offers 2 financial assistance programs for patients using Zydelig:

Brukinsa (zanubrutinib)

Brukinsa is a Bruton tyrosine kinase inhibitor used for the treatment of adults with mantle-cell lymphoma after at least 1 previous therapy.

BeiGene offers 3 financial assistance programs for patients who are prescribed Brukinsa:

Calquence (acalabrutinib) Capsules

Calquence is a Bruton tyrosine kinase inhibitor used for the treatment of adults with mantle-cell lymphoma who have received at least 1 previous therapy.

AstraZeneca Access 360 offers 2 financial assistance programs for patients using Calquence:

Imbruvica (ibrutinib) Capsules/Tablets

Imbruvica is a Bruton tyrosine kinase inhibitor used for the treatment of adults with mantle-cell lymphoma, after at least 1 previous therapy.

Pharmacyclics’ You&i Support Program offers 2 financial assistance programs for patients using Imbruvica:

You&i Instant Savings Program

Patients with private insurance will pay no more than $10 monthly for Imbruvica. Eligible patients may qualify for instant savings on their commercial insurance copay, deductible, and co-insurance medication costs for Imbruvica.

Johnson & Johnson Patient Assistance Foundation

This program provides Imbruvica free of charge to patients who meet certain financial limits and are either uninsured, underinsured, or enrolled in Medicare Part D.

Revlimid (lenalidomide) Capsules

Revlimid is a thalidomide analog used for the treatment of patients with mantle-cell lymphoma whose disease has relapsed or progressed after 2 therapies, one of which was Velcade.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Revlimid:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductible, copay, or co-insurance costs for eligible patients with private insurance who have been prescribed Revlimid. Patients pay a $25 copay, and BMS covers the remaining amount, up to $25,000 annually.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Revlimid, may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual, or $52,260 for a family of 2.

Tecartus (brexucabtagene autoleucel)

Tecartus is a CAR T-cell therapy (gene therapy) used for the treatment of adults with relapsed or refractory mantle-cell lymphoma.

Kite Pharma offers 1 financial assistance program for patients who have been prescribed Tecartus:

Kite Konnect

This program helps patients and healthcare teams throughout treatment with Tecartus. (For more information, call 844-454-5483.)

Velcade (bortezomib) for Injection

Velcade is a proteasome inhibitor used for the treatment of patients with mantle-cell lymphoma.

Takeda Oncology offers 2 financial assistance programs for patients using Velcade:

Velcade Reimbursement Assistance Program

For patients with Medicare, Medicaid, or private insurance, this program will help find supplemental coverage if needed and provide assistance with copays.

Velcade Patient Assistance Program

Patients without insurance coverage may qualify to receive Velcade free of charge through this program. Patient eligibility is based on household income, treatment setting, and medically appropriate need.

Brukinsa (zanubrutinib)

Brukinsa is a Bruton kinase inhibitor used for the treatment of adults with relapsed or refractory marginal-zone lymphoma who have received at least 1 anti-CD20-based regimen.

BeiGene offers 3 financial assistance programs for patients who are prescribed Brukinsa:

BeiGene Free Product Assistance

This program provides Brukinsa for free for patients who have no insurance or insufficient insurance. This program has certain financial and eligibility requirements.

Imbruvica (ibrutinib) Capsules/Tablets

Imbruvica is a Bruton tyrosine kinase inhibitor used for the treatment of marginal-zone lymphoma, a type of non-Hodgkin lymphoma, in patients who require systemic therapy and have received at least 1 previous anti-CD20-based therapy.

Pharmacyclics’ You&i Support Program offers 2 financial assistance programs for patients using Imbruvica:

You&i Instant Savings Program

Patients with private insurance will pay no more than $10 monthly for Imbruvica. Eligible patients may qualify for instant savings on their commercial insurance copay, deductible, and co-insurance medication costs for Imbruvica.

Johnson & Johnson Patient Assistance Foundation

This program provides Imbruvica free of charge to patients who meet certain financial limits and are either uninsured, underinsured, or enrolled in Medicare Part D.

Revlimid (lenalidomide) Capsules

Revlimid is a thalidomide analog used for the treatment of patients with marginal-zone lymphoma.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Revlimid:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductible, copay, or co-insurance costs for eligible patients with private insurance who have been prescribed Revlimid. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including the BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Revlimid, may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual, or $52,260 for a family of 2.

Ukoniq (umbralisib) Tablets

Ukoniq is a kinase inhibitor and PI3K-delta and CK1-epsilon, approved for the treatment of adults with relapsed or refractory marginal-zone lymphoma who have received 1 or more previous anti-CD20-based regimens.

TG Therapeutics offers 4 financial assistance programs for patients using Ukoniq:

Calquence (acalabrutinib) Capsules

Calquence is a Bruton tyrosine kinase inhibitor used for the treatment of adults with small lymphocytic lymphoma.

AstraZeneca 360 offers 2 financial assistance programs for patients who have been prescribed Calquence:

Copiktra (duvelisib)

Copiktra is a dual PI3 kinase inhibitor used for the treatment of adults with relapsed or refractory small lymphocytic lymphoma, after at least 2 other therapies.

Verastem Cares offers 3 financial assistance programs for patients who have been prescribed Copiktra:

Verastem Cares Patient Assistance Program

Patients who are uninsured and have an annual income of $150,000 or less may qualify to receive Copiktra for free.

Gazyva (obinutuzumab)

Gazyva is a CD20-directed cytolytic antibody used, in combination with Imbruvica or with Venclexta, for the first-line treatment of patients with small lymphocytic lymphoma.

Genentech Oncology offers 2 financial assistance programs for patients using Gazyva:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Gazyva, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Access to Care Foundation

This foundation provides Gazyva free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Gazyva is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.

Imbruvica (ibrutinib) Capsules/Tablets

Imbruvica is a Bruton tyrosine kinase inhibitor used for the first-line treatment of patients with small lymphocytic lymphoma (SLL), with or without 17p deletion. Imbruvica is also used, in combination with Gazyva, for the first-line treatment of patients with SLL.

Pharmacyclics’ You&i Support Program offers 2 financial assistance programs for patients who have been prescribed Imbruvica:

You&i Instant Savings Program

Patients who have private insurance will pay no more than $10 per month for Imbruvica. Eligible patients may qualify for instant savings on their commercial insurance copay, deductible, and co-insurance medication costs for Imbruvica.

Johnson & Johnson Patient Assistance Foundation

This program provides Imbruvica free of charge to patients who meet certain financial limits and are uninsured, underinsured, or enrolled in Medicare Part D.

Venclexta (venetoclax) Tablets

Venclexta is a BCL-2 inhibitor used for the treatment of adults with small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least 1 previous therapy. Venclexta is also used, in combination with Gazyva or with rituximab, for the first-line treatment of patients with SLL.

AbbVie and Genentech offer 2 financial assistance programs for patients who have been prescribed Venclexta:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Venclexta, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Venclexta free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Venclexta is also provided free for patients who are unable to afford their outof- pocket costs and cannot find other financial assistance.

Zydelig (idelalisib) Tablets

Zydelig is a kinase inhibitor used for the treatment of patients with small lymphocytic lymphoma after 2 or more systemic therapies.

Gilead, through Zydelig AccessConnect, offers 2 financial assistance programs for patients using Zydelig: